PASATRU

This brand name is authorized in United States.

Active ingredients

The drug PASATRU contains one active pharmaceutical ingredient (API):

`1`	Garetosmab UNII `KR9ZSKO5QE` - GARETOSMAB
	FOP is caused by gain-of-function mutations in the intracellular domain of activin receptor type 1 (ACVR1, also known as ALK2), a bone morphogenetic protein (BMP) type I receptor that is expressed in many tissues, including skeletal muscle and cartilage. In patients with FOP, mutant ACVR1 is activated by activin A resulting in heterotopic ossification. Garetosmab is a human IgG4 monoclonal antibody that specifically binds to and inhibits signaling by activin A to block the activation of FOP-mutant ACVR1 and reduce the formation and progression of new heterotopic bone lesions.
	Read more about Garetosmab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PASATRU Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	61755-012

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.